{
  "title": "With Promise of Legalization, Psychedelic Companies Joust Over Future Profits",
  "link": "https://www.nytimes.com/2022/10/25/health/psychedelic-drug-therapy-patents.html",
  "guid": "https://www.nytimes.com/2022/10/25/health/psychedelic-drug-therapy-patents.html",
  "atom:link": "",
  "description": "Cash rich start-ups are filing scores of patent claims on hallucinogens like magic mushrooms. Researchers and patient advocates worry high prices will make the therapies unaffordable.",
  "dc:creator": "Andrew Jacobs",
  "pubDate": "Tue, 25 Oct 2022 12:51:21 +0000",
  "category": [
    "Inventions and Patents",
    "Psychedelic and Hallucinogenic Drugs",
    "Psilocybin Mushrooms",
    "Therapy and Rehabilitation",
    "Mental Health and Disorders",
    "Research",
    "Start-ups",
    "United States"
  ],
  "media:content": "",
  "media:credit": "Tom Jamieson for The New York Times",
  "media:description": "George Goldsmith, co-founder and executive chairman of Compass Pathways in London."
}